Whistleblower Rebuffs Counterclaim for Disclosing Confidential Information
Client Alert | 1 min read | 05.20.16
In U.S. ex rel. Cieszynski v. LifeWatch Servs. (N.D. Ill., May 9), the court dismissed the defendant’s counterclaim against a former employee and FCA whistleblower, ruling that the whistleblower’s disclosure of protected patient information fell within the public policy protections for whistleblowers. As described in a post on the Whistleblower Watch Blog, there has been an increase in recent years of FCA defendants raising counterclaims based on breaches of confidentiality agreements, and this will likely remain an active area of litigation until the courts clearly define what documents an FCA whistleblower can take from an employer and how the whistleblower can use those documents to support FCA allegations.
Contacts
Insights
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies.
Client Alert | 8 min read | 04.27.26
Client Alert | 5 min read | 04.27.26
Drift Protocol Exploit: Why “Social Trust” Is the Newest Cybersecurity Gap
Client Alert | 4 min read | 04.27.26
Gaming Addiction Litigation: Turner v. Epic Games & Roblox and What It Means for the Industry
